Gilles Freyer

13.4k total citations · 2 hit papers
213 papers, 7.7k citations indexed

About

Gilles Freyer is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Gilles Freyer has authored 213 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Oncology, 50 papers in Reproductive Medicine and 43 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Gilles Freyer's work include Ovarian cancer diagnosis and treatment (50 papers), Cancer Treatment and Pharmacology (48 papers) and PARP inhibition in cancer therapy (27 papers). Gilles Freyer is often cited by papers focused on Ovarian cancer diagnosis and treatment (50 papers), Cancer Treatment and Pharmacology (48 papers) and PARP inhibition in cancer therapy (27 papers). Gilles Freyer collaborates with scholars based in France, United States and United Kingdom. Gilles Freyer's co-authors include Jim Cassidy, D. Papamichael, H. Cortés-Funes, Andrés Cervantes, N Le Bail, F. Morvan, Daniel Hendler, Andrea Bonetti, Abdel Hmissi and Arié Figer and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer.

In The Last Decade

Gilles Freyer

206 papers receiving 7.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

2000 3.0k citations Aimery de Gramont, Arié Figer et al. Journal of Clinical Oncology profile →
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

2012 539 citations Thomas Bachelot, C. Bourgier et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Gilles Freyer

Since Specialization

Citations

This map shows the geographic impact of Gilles Freyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gilles Freyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gilles Freyer more than expected).

Fields of papers citing papers by Gilles Freyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gilles Freyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gilles Freyer. The network helps show where Gilles Freyer may publish in the future.

Co-authorship network of co-authors of Gilles Freyer

This figure shows the co-authorship network connecting the top 25 collaborators of Gilles Freyer. A scholar is included among the top collaborators of Gilles Freyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gilles Freyer. Gilles Freyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin 2025 ·European Journal of Cancer ·(unknown), (unknown), Sylvie Chabaud, (unknown), (unknown), Aude Fléchon, Helen Boyle, Armelle Vinceneux, F. Bérard, Benoît You, Gilles Freyer, (unknown), Sophie Tartas, Mona Amini‐Adlé	1
2	Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial 2025 ·Nature Communications ·Max Piffoux, Alexandra Léary, Philippe Follana, Cyril Abdeddaim, Florence Joly, Sylvie Bin, (unknown), Anaïs Boulai, Céline Callens, Laurent Villeneuve, (unknown), Vérane Schwiertz, Gilles Freyer, Manuel Rodrigues, Benoît You	1
3	Intraperitoneal Nivolumab after Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy in Advanced Ovarian Cancer: A Phase I Study with Expansion Cohort 2024 ·Clinical Cancer Research ·Pauline Corbaux, Gilles Freyer, Olivier Gléhen, Benoît You, Naoual Bakrin, (unknown), (unknown), Christophe Sajous, Max Piffoux, Julien Péron, (unknown), Léa Payen, Vahan Képénékian	3
4	Prognostic Value of the Modeled Prostate-Specific Antigen KELIM Confirmation in Metastatic Castration-Resistant Prostate Cancer Treated With Taxanes in FIRSTANA 2024 ·JCO Clinical Cancer Informatics ·(unknown), Stéphane Oudard, Olivier Colomban, Karim Fizazi, Denis Maillet, Oliver Sartor, Gilles Freyer, Benoît You	2
5	Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a “real-life setting” 2024 ·Journal of Gynecologic Oncology ·(unknown), Olivier Colomban, Maaike A. van der Aa, Gilles Freyer, Gabe S. Sonke, Roy F.P.M. Kruitwagen, Benoît You	8
6	Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study 2024 ·The Breast ·Gilles Freyer, Noelia Martínez-Jáñez, Bożena Kukiełka-Budny, Małgorzata Ułańska, Hugues Bourgeois, Montserrat Muñoz-Mateu, Serafín Morales, (unknown), Laura Cortesi, Tamás Pintér, Markéta Palácová, (unknown), Edgar Petru, Johannes Ettl, (unknown), G. Villanova, (unknown), (unknown), Ana Rodrigues, Marina Elena Cazzaniga	1
7	Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access? 2024 ·ESMO Open ·Carmine Valenza, Dario Trapani, François‐Clément Bidard, (unknown), Javier Cortés, Nicholas C. Turner, (unknown), Frédérique Penault‐Llorca, Gilles Freyer, Mónica Arnedos, (unknown), Sibylle Loibl, Barbara Pistilli, Giuseppe Curigliano	2
8	Impact of Age on Poly(ADP-Ribose) Polymerase Inhibitor (PARPi)-Induced Lymphopenia: A Scoping Review of the Literature and Internal Analysis of a Retrospective Database 2023 ·Drugs & Aging ·(unknown), Maël Heiblig, Gilles Freyer, Hervé Ghesquières, Claire Falandry	2
9	HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments 2023 ·Cancers ·(unknown), Zineb Benbrahim, (unknown), (unknown), Pauline Corbaux, Gilles Freyer	11
10	Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study 2022 ·The Lancet Healthy Longevity ·Claire Falandry, Fanny Pommeret, Laurence Gladieff, Fabien Tinquaut, Domenica Lorusso, Marie‐Ange Mouret‐Reynier, Véronique D’Hondt, (unknown), Anne Floquet, Sophie Abadie‐Lacourtoisie, Pierre-Emmanuel Brachet, Laëtitia Stefani, Frédérique Rousseau, Jean‐Sébastien Frenel, Francesco Del Piano, Marja Komulainen, (unknown), Olivier Trédan, Éric Pujade-Lauraine, Gilles Freyer	7
11	PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers 2022 ·Cancers ·L. Collet, Julien Péron, Frédérique Penault‐Llorca, Pascal Pujol, Jonathan Lopez, Gilles Freyer, Benoît You	7
12	Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial 2020 ·Journal of Clinical Oncology ·Benoît You, Pierre‐Adrien Bolze, Jean‐Pierre Lotz, Jérôme Massardier, Laurence Gladieff, Florence Joly, Touria Hajri, Delphine Maucort‐Boulch, Sylvie Bin, Pascal Rousset, Mojgan Devouassoux‐Shisheboran, Adeline Roux, (unknown), (unknown), Carole Langlois‐Jacques, (unknown), Laurent Villeneuve, Gilles Freyer, François Golfier	75
13	Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study 2019 ·Clinical Cancer Research ·Olivier Colomban, Michel Tod, Alexandra Léary, Isabelle Ray‐Coquard, Alain Lortholary, (unknown), Jacobus Pfisterer, Andreas du Bois, Christian Kurzeder, Alexander Burges, Julien Péron, Gilles Freyer, Benoît You	37
14	Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients 2018 ·Cancer Chemotherapy and Pharmacology ·Olivia Le Saux, Aurélie Bourmaud, Catherine Rioufol, Olivier Colomban, Jérôme Guitton, Vérane Schwiertz, Véronique Régnier Denois, Benoît You, Florence Ranchon, (unknown), Pascal Girard, Franck Chauvin, Gilles Freyer, Michel Tod, Émilie Hénin, V. Trillet-Lenoir	15
15	A phase 1b study of Trebananib plus Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in patients with HER2+ locally recurrent or metastatic breast cancer 2015 ·Open Repository and Bibliography (University of Liège) ·Peter A. Kaufman, Gilles Freyer, Margaret Kemeny, Anthony Gonçalvès, Guy Jérusalem, Alison Stopeck, (unknown), Florence Dalenc, Nadeeshani Nanayakkara, Benjamin Wu, Cheryl A. Pickett, Hans Wildiers	1
16	Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors 2012 ·Clinical Cancer Research ·Nicolás Isambert, Gilles Freyer, Sylvie Zanetta, Benoît You, P. Fumoleau, Claire Falandry, Laure Favier, Sylvie Assadourian, Karen Soussan-Lazard, (unknown), V. Trillet-Lenoir	31
17	Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study breakdown → 2012 ·Journal of Clinical Oncology ·Thomas Bachelot, C. Bourgier, Claire Cropet, Isabelle Ray‐Coquard, Jean-Marc Ferrero, Gilles Freyer, Sophie Abadie‐Lacourtoisie, Jean‐Christophe Eymard, Marc Debled, Dominique Spaëth, Éric Legouffe, Djelila Allouache, Claude El Kouri, Éric Pujade-Lauraine	539
18	Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. 2011 ·PubMed ·Gilles Freyer, (unknown), G. Milano, Étienne Chatelut, Christine Rebischung, Jean‐Pierre Delord, Yacine Merrouche, Gérard Lledo, Marie‐Christine Etienne, Claire Falandry	14
19	Cancer Patients Who Experienced Diagnostic Genetic Testing for Cancer Susceptibility 2002 ·Cancer Epidemiology and Prevention Biomarkers ·Valérie Bonadona, P. Saltel, Françoise Desseigne, H. Mignotte, Jean‐Christophe Saurin, Qīng Wáng, Olga M. Sinilnikova, Sophie Giraud, Gilles Freyer, Henri Plauchu, Alain Puisieux, Christine Lasset	1
20	Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer breakdown → 2000 ·Journal of Clinical Oncology ·Aimery de Gramont, Arié Figer, Michel Seymour, M. Homerin, Abdel Hmissi, Jim Cassidy, C. Boni, H. Cortés-Funes, Andrés Cervantes, Gilles Freyer, D. Papamichael, N Le Bail, Christophe Louvet, Daniel Hendler, Filippo de Braud, C. Wilson, F. Morvan, Andrea Bonetti	3040

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact